Biocryst Pharmaceuticals (BCRX) Net Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | -10.13% |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | -98.96% |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | -8.34% |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | 36.60% |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | -35.85% |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | 67.39% |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | -96.44% |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn | -25.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.93% |
| Mar 31, 2026 | 36.60% |
| Dec 31, 2025 | -29.36% |
| Sep 30, 2025 | 47.95% |
| Jun 30, 2025 | 70.36% |
| Mar 31, 2025 | 26.01% |
| Dec 31, 2024 | -69.57% |
| Sep 30, 2024 | 54.31% |
| Jun 30, 2024 | 29.26% |
| Mar 31, 2024 | 15.75% |
| Dec 31, 2023 | -30.67% |
| Sep 30, 2023 | 27.19% |
| Jun 30, 2023 | -28.41% |
| Mar 31, 2023 | -130.00% |
| Dec 31, 2022 | -11.93% |
| Sep 30, 2022 | -86.77% |
| Jun 30, 2022 | -310.41% |
| Mar 31, 2022 | -142.19% |
| Dec 31, 2021 | 139.69% |
| Sep 30, 2021 | -36.72% |